Podcasts about Caris

Lexus RZ550e Review; a fun book; Days of Thunder is coming; sauce contests; Countach update; and...Patreon questions include:This JDM car is not good for 16 year oldsFun cars for expecting parentsHow to hate big tech while taking Waymos?Non-German $50k road trip sedan?Small deal-breakers when buying a carIs a used S8 a good long-distance cruiser?Best manual Honda for $10k-20k?Powertrain for ground-up Lotus 7 build?How to do a cheap(er) 993 buildGridlife adviceDo body kits add value?And more! Recorded 9/7/2026 Show Notes:EthosGet your free quote at https://ETHOS.com/tire Factor Head to https://factormeals.com/tire50off and use code tire50off to get 50 percent off and 1 free breakfast item per box for 1 year, while supplies last until 10/31/2026. See website for more details. DeleteMeGet 20% off your DeleteMe plan when you go to www.joindeleteme.com/tire and use promo code TIRE at checkout.Want your question answered? To listen to the episode the day it's recorded? Want to watch the live stream, get ad-free podcasts, or exclusive podcasts? Join our Patreon: https://www.patreon.com/thesmokingtirepodcastUse Off The Record! and ALWAYS fight your tickets! For a 10% discount on your first case go to https://www.offtherecord.com/TST#cars #comedy #podcastInstagram:https://www.Instagram.com/thesmokingtire https://www.Instagram.com/therealzackklapmanClick here for the most honest car reviews out there: https://www.youtube.com/thesmokingtire Want your question answered? Want to watch the live stream, get ad-free podcasts, or exclusive podcasts? Join our Patreon: https://www.patreon.com/thesmokingtirepodcast Use Off The Record! and ALWAYS fight your tickets! Enter code TST10 for a 10% discount on your first case on the Off The Record app, or go to http://www.offtherecord.com/TST. Watch our car reviews: https://www.youtube.com/thesmokingtire Tweet at us!https://www.Twitter.com/thesmokingtirehttps://www.Twitter.com/zackklapman Instagram:https://www.Instagram.com/thesmokingtirehttps://www.Instagram.com/therealzackklapman

Caris Holt on Being a Sibling to a Child with Special Needs Becky Davidson talks with Caris Holt, daughter of Carrie Holt and sister of Toby, about what it means to grow up as a sibling to someone with disabilities and special needs. Caris shares how that shaped her family life, her faith, and her sense of identity, while also naming the grief, loneliness, and pressure that can come with the role.In this conversation, Becky and Caris discuss the hidden emotional load on siblings, the importance of being seen as an individual, and how counseling and faith have helped Caris process what she feels. Caris also shares the creative interests and church leadership that help define her beyond her family role. Key topics Karis introduces herself as the youngest of four, with three older brothers, and shares the creative things she loves: fiction writing, fantasy, drawing, piano, music, horseback riding, and faith. She talks about leading third grade girls at church and how their openness has taught her that there is no such thing as a dumb question. Karis describes growing up in a home where nurses and care support were often present, which reduced privacy and made her feel more independent at a young age. She shares how being Toby's sister has brought unexpected gifts, including family closeness, resilience, prayer, grief shared together, and special experiences through a nonprofit called A Kid Again. Becky and Karis discuss the visibility of Toby's disability and how easy it is for others to reduce him to his wheelchair instead of seeing his humor, kindness, and compassion. Karis opens up about the pressure she felt to stay quiet, blend into the background, and not take up too much attention because Toby needed so much care. She reflects on learning to take up space, name her needs, and accept that she is also a person whose needs matter. Karis explains that special needs impact the whole family, not just the child with the diagnosis, and says siblings need to be asked how they are doing too. She shares how her parents supported her by making room for her own interests, friendships, and rest away from the demands of home. Karis describes how family, cousins, and church relationships have helped Toby feel included and have given both siblings a sense of belonging. She talks about how she and Toby have grown closer over time, including deeper conversations and shared interests like Star Wars. Karis explains how faith, especially trusting God's faithfulness through hard seasons, has given her purpose and a deep relationship with Jesus. She shares how counseling has helped her put words to her experiences, identify triggers, and process emotions in a healthy way. Karis encourages other siblings who feel guilt, anger, or frustration to remember they are not alone and that they can bring those feelings to Jesus for healing.

S1E9: Caris Life Sciences Series Part 3 of 3: The Future: AI and Large-scale Molecular Data Shaping Next-Generation Oncology Host Shahid Shah with his guest Dr. Milan Radovich, Senior VP and Chief Scientific Officer at Caris Life Sciences To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

S1E8: Caris Life Sciences Series - Part 2 of 3: The Access: Liquid Biopsy and Expanding Access to Precision Oncology Host Shahid Shah with his guest Joseph C. Murray, MD, PhD, is Senior Medical Director at Caris Life Sciences. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

S1E7: Caris Life Sciences Series - Part 1 of 3: The Science: Advancements in molecular profiling (WES + WTS) and impact on cancer care Host Shahid Shah with his guest James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance™ (Caris POA). To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Caris Life Science Aktie: weltbewegende Krebs Früherkennung durch AI möglich + schon profitabel

What standard GP testing misses, and why it matters more for athletes. Several months ago I wrote a LinkedIn post about my own decision to start taking statins, after several years of resisting that path. Katherine Caris-Harris, a performance nutritionist and fellow triathlete, reached out afterwards. She felt there were gaps in the conversation, and she was right. Katherine is a degree-qualified nutritionist who works with what she calls corporate athletes, driven, high-performing people who often push themselves too hard across every area of life. In this episode we dig into the limitations of standard GP cholesterol testing, why LDL alone is a poor predictor of cardiovascular risk, the role of insulin resistance and thyroid function in driving cholesterol up, what the actual numbers needed to treat for statins really look like, and why cholesterol itself is essential, not the villain it's often made out to be. This isn't an anti-medication conversation. Katherine isn't here to tell you what to do. It's about giving you the fuller picture so you can make an informed decision for yourself, whatever that ends up being. 5 KEY POINTS LDL alone is a poor predictor of risk. Standard GP testing estimates LDL using a crude calculation, and doesn't account for particle size or how easily those particles are damaged by inflammation. Better markers exist, but aren't routinely offered. ApoB and Lipoprotein(a) give a far more accurate picture of cardiovascular risk than standard LDL testing, but most GPs don't test for them due to cost. The number needed to treat varies hugely. For primary prevention in a low risk group, you may need to treat 100 to 200 people with statins to prevent one cardiovascular event. That context rarely makes it into the conversation. Insulin resistance can quietly drive cholesterol up. Even lean, fit endurance athletes can develop elevated blood sugar and insulin resistance through excessive use of gels, energy drinks and fasted training. Cholesterol is essential, not the enemy. It's required for hormone production, cell repair, brain health and vitamin D synthesis. The real driver of arterial damage is oxidative stress and inflammation. 3 TAKEAWAYS Get tested properly before deciding. Standard GP panels are a useful starting point but rarely tell the full story, particularly for athletes. Context matters more than a single number. Genetics, insulin resistance, thyroid function and inflammation all contribute to your real cardiovascular risk. Make your decision from a position of knowledge, not fear. Whatever you choose to do, do it with the fuller picture in front of you.   KILLER QUOTE "You wouldn't ignore your FTP test results. So why would you ignore what's actually happening under the hood with your cardiovascular health?" CONNECT with Katherine Katherine Caris-Harris is a performance and functional nutritionist working with driven, high-performing clients juggling demanding careers with serious training. She is also a long-time age-group triathlete.

Cari hat für die letzte Episode ohne Manuel noch einmal einen besonderen Überraschungsgast eingeladen: Mathias, unser Easy German Korrespondent aus Österreich, erzählt von der Vienna Pride in Wien und wie er spontan Arnold Schwarzenegger getroffen hat. In "das nervt" fragt Cari Mathias, warum er eigentlich nie genervt ist. Zum Abschluss beantworten wir eine Hörerfrage zum Österreichischen Dialekt und stellen Caris Übersetzungskünste auf die Probe.   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsor Lingoda: Join the ultimate challenge with Lingoda Sprint this summer and get up to 100% cashback when completing all classes. Get an additional 50€ discount when you sign up today with our code EASYG50: https://try.lingoda.com/Lingoda_EasyGermanJune   Das ist schön: Vienna Pride Vienna Pride

Wir sprechen über die bevorstehende Fußball-Weltmeisterschaft und warum sie bei uns sowohl Vorfreude als auch Skepsis auslöst. Außerdem kündigen wir ein Meetup auf der Seine in Paris an, hören eine "das nervt"-Geschichte aus dem deutschen Straßenverkehr und teilen Ressourcen für einen Umzug nach Deutschland. Zum Schluss geht es um viralen Internet-Ruhm, Social Media und die Frage, was Berühmtheit mit einem Menschen macht.   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsoren Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Hausmitteilung: Wir kommen nach Paris Wir kommen nach Paris! Am 1. August könnt ihr uns treffen und gemeinsam mit uns und dem Easy French Team eine Bootstour auf der Seine machen. Alle Infos und Tickets findet ihr auf: easygerman.org/meetups   Eure Fragen Amanda aus den USA fragt: Was sind die besten Ressourcen für einen Umzug nach und Neustart in Deutschland? Website: https://www.make-it-in-germany.com/ (Bundesregierung) YouTube-Kanal: Simple Germany Website: All About Berlin Vergleichsportal: Check24 - das Vergleichsportal Vergleichsportal: Verivox Website: Finanztip Podcast: Everyone Is Moving To Berlin Hast du eine Frage an uns? Auf easygerman.fm kannst du uns eine Sprachnachricht schicken.   Empfehlung der Woche Hype - Die Noelgoescrazy-Story (ZDF) 37 Grad: Über 40 Millionen folgen ihm: Was steckt hinter dem Hype um Noelgoescrazy? (YouTube) Cari auf Instagram Manuel auf Instagram   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership

Subscribe on Patreon and hear this week's full patron-exclusive episode here: https://www.patreon.com/posts/160543761 Beatrice speaks with Alice, Fish, and Caris from a Turtle Island-based Free Clinic about care as a site of struggle, abolishing the medical industrial complex, and their experiences engaging in mutual aid and survival work. Runtime 2:30:51 This is the fifth episode in a new series called All Care for All People (ACAP), as Artie describes in an introduction at the top of this episode. Over the coming weeks we will be speaking to people engaged in mutual aid survival programs, working across a variety of tactics, locations, and organizational structures, who are each stepping in, in different ways, to provide care where it is needed. MERCH STORE IS BACK! Patrons get a code for 10% off all orders. Find it at https://www.deathpanel.net/merch We're testing out a new Bookshop.org page (still under construction), where you can find books by past guests and book recommendations from the hosts. Find it here: https://bookshop.org/shop/deathpanel Show links: Get Health Communism here: https://bookshop.org/a/118130/9781839765179 Find Tracy's book Abolish Rent here: https://bookshop.org/a/118130/9798888902523

.

.

Wir sitzen über den Dächern von Wien und sprechen über Hotelzimmer-Chaos, Double-Dipped Tee und unser Easy-Languages-Netzwerk-Treffen. Caris teilt ihre neue Idee, Sprachenlernen und Fahrradfahren zu kombinieren. Im Thema der Woche verraten wir euch, wie man internationale Markennamen in Deutschland ausspricht. Außerdem wollen wir von euch wissen: Sollen wir nach Brasilien reisen? Und: Eine Video-Empfehlung zum Aldi-Hype in den USA.   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsoren Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Das ist schön: Easy Languages Netzwerktreffen Easy French Kanal Alle Easy Languages Teams   Thema der Woche: Internationale Brands 15 German Brands You Might Pronounce Wrong (Easy German Videos)   Unsere Hausmitteilung: Easy German-Reise nach Brasilien? Wir möchten im Oktober 2026 vielleicht nach Brasilien reisen und suchen nach Ideen und Orten für Videodrehs und Meetups! Wenn du Ideen hast, dann melde dich gerne auf: easygerman.org/brazil Empfehlung der Woche ATLAS: Der absurde Aldi-Hype in den USA (YouTube)   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership

Sports and science go hand in hand, especially when it comes to softball and baseball. Join Molly and co-host Caris as they answer more of your questions about these two ballgames. Like why are bats measured in ounces? Or why do some players wear black paint under their eyes? Plus, we'll hear more of your chants and guess an all new Mystery Sound. Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) June 6 - Michigan Theater, Ann Arbor, MI June 20 - Southern Theater, Columbus, OH June 21 - Turner Hall Ballroom, Milwaukee, WI Click here for a transcript of this episode.

Sports and science go hand in hand, especially when it comes to softball and baseball. Join Molly and co-host Caris as they answer more of your questions about these two ballgames. Like why are bats measured in ounces? Or why do some players wear black paint under their eyes? Plus, we’ll hear more of your chants and guess an all new Mystery Sound. Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) June 6 - Michigan Theater, Ann Arbor, MI June 20 - Southern Theater, Columbus, OH June 21 - Turner Hall Ballroom, Milwaukee, WI Click here for a transcript of this episode.See omnystudio.com/listener for privacy information.

The Beauty (Image Comics) vs. FX's Adaptation: Ozempic, Body Horror, and Ryan MurphyWhat if an STD could make you the most perfect version of yourself? This week on Collecting Issues, Benjamin and Michael read The Beauty (Vol. 1, Issues #1-6), the 2016 hit by Jeremy Haun and Jason A. Hurley.We compare the original "buddy cop" police procedural comic against the new 2026 FX on Hulu adaptation produced by Ryan Murphy. From the eerily prescient social commentary on modern beauty standards (GLP-1s, Ozempic face) to the explosive consequences of the virus, we break down why this story hits harder in a post-COVID world.In This Episode We Discuss:The Elevator Pitch: Imagine a sexually transmitted disease that guarantees physical perfection for two years—before you spontaneously combust.Comic vs. TV: How the comic functions as a tight "90-minute action movie" versus the sprawling, body-horror-heavy miniseries.Cultural Prescience: Reading a 2016 comic in 2026; how The Beauty predicted the toxic positivity and division of modern weight-loss culture.The Ryan Murphy Treatment: A look at the FX adaptation's star-studded cast (Evan Peters, Ashton Kutcher, Rebecca Hall) and the controversial decision to use "recasting" as a plot device.Character Deep Dive: Why Detectives Vaughn and Foster work as grounded leads, and why the villainous Carves feels like a comic book archetype dropped into a gritty drama.Coming Up Next:We are reading Absolute Martian Manhunter Vol. 1 by Deniz Camp and Javier Rodriguez. Join us as we explore this dark, conspiratorial reimagining of J'onn J'onzz in the new DC "All In" universe.Follow the Podcast:Join the Discord and read alongRead Our SubstackFollow us on InstagramFollow us on TiktokWatch us on YoutubeIf you enjoyed this episode, please leave us a review on Spotify or Apple Podcasts. It helps more than you know!Time Stamps:00:00 Welcome to Collecting Issues + why we're covering The Beauty (and the FX show)01:53 Spoiler warning & how to follow along (read Vol. 1, watch eps 1–2)03:04 The elevator pitch: an STD that makes you beautiful04:37 Worldbuilding: 800 days, stigma, and the ‘burn from the inside' twist09:26 Who made this? Jeremy Haun & Jason A. Hurley origin story11:16 Publishing & rights: Image, Ignition Press, and the FX tie-in reprint14:07 Why Vol. 1 feels like a tight ‘movie' + anthology series after issue #617:41 Pre-COVID vs post-COVID reading: stigma, Ozempic parallels, and ‘earned' beauty28:54 Meet the cast: Vaughn & Foster, the Beauty Task Force, and the conspiracy setup30:55 Stock characters done well? Buddy-cop structure, Caris the hitman, and what works/doesn't34:59 Caris the Masked Henchman: Grounded World vs Over-the-Top Villainy36:24 Best Scenes & Twists: The Celebrity Spokesperson Hit and Foster's Mirror Reveal38:49 Consequences Escalate: Collateral Damage and the Air-Traffic Controller Disaster39:19 Art That Serves the Story: Same-Face Syndrome, Visual Clarity, and Comic Fundamentals40:43 Covers, Character Design & Horror: Mannequin Imagery and ‘Non-Beauty' Markers43:48 The Cure Ending: Body Horror, Consent, and the Ethics of Forcing a ‘Solution'48:26 Cathartic Payoff: Vaughn Takes Down Caris (and Why Characters Act Smart)50:37 Netflix/FX Adaptation Talk: Ryan Murphy, Casting, and How the Show Changes the Premise01:04:36 Final Verdict & Wrap-Up: Comic vs Series, Where to Comment, and Next Book Club Pick Hosted on Acast. See acast.com/privacy for more information.

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Eh, Yo! This week we talk Jai Alai. More specifically Throwback: Jai Alai Heroes by Astro Crow Games. Throwback: Jai Alai Heroes was first introduced in episode 46 and 102. Brian and Caris took their game Throwback: Jai Alai Heroes from a 4-player game to a 2-player game so that It could go into their prototype cabinet. Throwback: Jai Alai Heroes can be played today at Leaderboards Arcade, Arcade Monster I-Drive location, and 7 more arcades in the near future.We dive into how Throwback! Jai Alai Heroes was made, how the team came together, and why they have decided to release it as an arcade game. Join us while we get to know this team from Orlando.If you like what we are doing here at Indie Arcade Wave don't forget to like, share, and subscribe. It means the world to us and will help the wave grow, so we can ride it together.If you are looking to buy new or used Stern pinballs, Food Fight Frenzy, Ice Cold Beer Remakes, Claw Machines, or Indie Arcade Games email me at Indiearcadewave@gmail.com.Indie Arcade WavePinballs: https://compulsivepinball.com/Website: https://www.indiearcadewave.comYoutube: https://www.youtube.com/c/IndieArcadeWaveTiktok: https://www.tiktok.com/@indiearcadewaveInstagram: https://www.instagram.com/indiearcadewave/Twitter: https://twitter.com/indiearcadewaveDiscord: https://discord.gg/6GntJQN Podcast: https://open.spotify.com/show/6dFWBTnIroJdBla3hi9SAK Bitchute: https://www.bitchute.com/channel/RckLgQBWwOAS/ Odyssey: https://odysee.com/@IndieArcadeWave:5Rumble: https://rumble.com/c/c-2032648Astro Crow:Facebook: https://www.facebook.com/AstroCrowInstagram: https://www.instagram.com/astrocrowgames/Reddit: https://www.reddit.com/r/JaiAlaiHeroes/Twitter: https://twitter.com/AstroCrowGamesCaris Instagram: https://www.instagram.com/caris.captures/

Koen Caris over Stad O. | Boekhandel Stumpel Almere   In deze aflevering vertelt Koen Caris over zijn nieuwe roman Stad O. Hij vertelt hoe vraagstukken uit zijn eigen leven hem op het idee voor Stad O. brachten, over de personages in het boek, die soms moeten wegkijken in ruil voor een comfortabel leven. Ook vertelt hij wat hij mee zou nemen uit Stad O. naar het echte leven. In Boekhandel Stumpel in Almere geeft Asnyox van Wee mooie boekentips.    Boekentips   Stad O. - Koen Caris - www.libris.nl/9789025473532   Kleine wonderen in de middernachtbakkerij - Lee Onhwa - www.libris.nl/9789401625159  Het laatste verhaal van Jamie Gunn - Thomas Olde Heuvelt - www.libris.nl/9789044658491  Emily Wildes ecyclopedie der feeën - Heather Fawcett - www.libris.nl/9789020556667 Geweten - Maurits de Bruijn - www.libris.nl/9789493399174  Albatros - Yorick Goldewijk - www.libris.nl/9789021686608 Geld verdienen - Hanna Bervoets - www.libris.nl/9789493420243              Trots en Vooroordeel - Jane Austen - www.libris.nl/9789403855110  Blackwater-box - Michael McDowell - www.libris.nl/9789401623353  De Bijbel - www.libris.nl/9789465113135

Everyone touched by cancer knows treatments vary depending on the type of cancer. Now, with precision medicine for some cancers, treatments can be tailored to that cancer. In this podcast, Dr. James Hamrick, MD, MPH, explains what precision medicine means for cancer patients and updates listeners on developments in testicular cancer treatments. Dr. Hamrick is the chairman of the Caris Precision Oncology Alliance, known as Caris POA at Caris Life Sciences. He leads a global network of top cancer centers and research institutions dedicated to advancing precision oncology and biomarker-driven research, and he will tell us all about it. Dr. Hamrick is board-certified in internal medicine, medical oncology, and hematology. He earned his MD and MPH in epidemiology from the University of North Carolina and completed his residency and fellowship at the University of California, San Francisco.Now - back to precision medicine. Here's what Dr. Hamrick explains in the podcast.00:09:55"When we treat a cancer, it's all about hitting the cancer, the bad part, and not hurting the rest of the person. And so the more we understand the targets we should be hitting in these tumors, the better we can design treatments that hit those targets and leave the rest of the cells in a person's body alone."What does that mean? "It means fewer side effects, so more effectiveness. So when you hear precision medicine, think about this: this is where my doctor is not just treating me for cancer. Not just treating me for lung cancer, but is working to understand exactly what is driving my cancer and how can we best target that so I have the best outcome, meaning we can kill those cancer cells, right?"And the fewest side effects. That's really precision oncology. Biomarkers bio. We all know from high school biology class that the life sciences markers are the targets. So these are the targets that we can now use at Caris and other vendors. We can say, hey, that's the problem here."It's not just one testicular cell that went bad; it's one that has this certain molecular profile. So I tell patients: You should ask your doctors, Hey, what biomarkers do we care about? What is important? What are we targeting? What's valuable here?"And that's part of becoming fluent in the language of your cancer, which, as many caregivers know, is really important."Dr. Hamrick talks more about testicular cancer and the need to find genetic biomarkers for it. He explains that and related research about testicular and other types of cancer in this episode of Don't Give Up on Testicular Cancer from the Max Mallory Foundation. Links:Caris Precision Oncology Alliance - Caris POAhttps://www.carislifesciences.com/partners/caris-precision-oncology-alliance/James Hamrick, MD, MPHhttps://www.carislifesciences.com/bio/james-hamrick-md-mph/Max Mallory Foundationhttps://www.maxmalloryfoundation.comDon't Give Up on Testicular CanceSend us a textSupport the showFind us on Twitter, Instagram, Facebook & Linkedin. If you can please support our nonprofit through Patreon.

Koen Caris is schrijver. Hij schrijft toneelstukken, romans, hoorspelen, museale teksten en non-fictie. Voorbeelden van zijn werk zijn het toneelstuk ‘MIJN', over een afgelegen mijndorp, en zijn roman ‘Stenen eten', die hem de Hebban Debuutprijs opleverde. Nu verschijnt zijn roman ‘Stad O'. Het boek gaat over het elite leven in stad O. Alles verloopt vlekkeloos totdat een stel op onderzoek uitgaat, en onverklaarbare dingen ontdekt. Daarnaast schreef Caris de voorstelling ‘Hoge Bomen', de nieuwe lunchvoorstelling van Theater Bellevue. Hierin stelt hij de vraag hoe we moeten omgaan met MeToo-daders wanneer zij terugkeren in de samenleving en naar hun werk. Femke van der Laan gaat met Koen Caris in gesprek.

What happens when we stop talking about kids with learning differences — and start listening to them? Kids are the experts in their own experience. When we truly listen, we all learn.Today we're joined by 15-year-old Caris, a smart and determined teen with dyslexia, and her dad, Kevin. In this honest conversation, they talk about the everyday challenges and small wins of growing up with a learning difference. Caris shares what she wishes more people understood about dyslexia and how she's found confidence in unexpected places. And she introduces “Through My Eyes,” a new digital experience from Understood.org that lets you step into her world.Want to learn more about her story? Explore Through My Eyes at Understood.org and help others see your child the way you do.For more on this topicSigns of dyslexia in high schoolSigns of dyslexia in grade schoolPodcast: What if I think my child might have dyslexia?Timestamps(01:50) Growing up with dyslexia(06:19) Facing stigma around learning disabilities(11:17) How “Through My Eyes” reframed their experience(13:06) Telling friends about her diagnosisFor a transcript and more resources, visit the In It show page on Understood.org. We love hearing from our listeners! Email us at init@understood.org. Explore Through My Eyes today. Step into the world of three kids with ADHD, dyslexia, and dyscalculia — helping you see differently so you can act differently.Understood.org is a nonprofit organization dedicated to empowering people with learning and thinking differences, like ADHD and dyslexia. If you want to help us continue this work, donate at understood.org/give

The new season of Business Class News's Race to the Start Line podcast launched with a conversation that was both deeply personal and profoundly forward-looking. Host Karl Woolfenden sat down with two leaders from Caris Life Sciences—Dr. David Spetzler, President and Chief Scientific Officer, and Dr. James Hamrick, Chairman of the Caris Precision Oncology Alliance —for a discussion on how Caris is transforming the future of cancer care. Woolfenden framed the conversation with personal reflections, sharing how recent losses in his own circle to cancer heightened his awareness of the need for innovation in oncology. “It tightened my awareness,” he said, “of how important it is to spotlight the companies and individuals driving meaningful progress.” Tackling the Complexity of Cancer Caris Life Sciences is a leader in molecular profiling and precision medicine, advancing how oncologists understand and treat cancer. Dr. Spetzler emphasized just how complicated this mission is: “Yeah, so I think what the patents demonstrate is that we're really on the cutting edge of trying to understand cancer. And the complexity of cancer is really quite staggering, because there are no two diseases that are the same.” He explained that Caris has built one of the world's largest datasets in cancer biology. “One of the things that we've been able to do is amass an enormous data set. We're approaching having profiled a million patients, and one of the great advantages that gives us is we can start to understand—from previous patients—new patients' status, and direct them towards the better drugs that are going to help them live longer.” From Science to the Patient Bedside Where Spetzler focused on the science, Dr. James Hamrick provided a clinical lens on the company's work. He reflected on his journey as both a practicing oncologist and now a leader at Caris. “The founder of Caris, and Dr. Spetzler who has been there since 2009, was always that connection point between the science and the patient. And that's where I focus—making sure what we're doing actually makes a difference in the clinic.” Hamrick highlighted the importance of ensuring that breakthroughs aren't confined to research institutions but are accessible to patients everywhere: “Too often, patients in community hospitals don't benefit from the latest advancements available at large academic medical centers. At Caris, we're working to close that gap.” Humanizing the Science The conversation underscored the human stakes of the work. Both leaders emphasized that the mission isn't just about data or discovery—it's about outcomes. Dr. Spetzler summed it up: “Science is only as valuable as the difference it makes in the real world. That's what drives us every day.” Scaling Innovation for the Future For Caris, growth means more than company expansion—it means scaling the reach of its technology so that physicians everywhere have the tools to personalize cancer care. This, Woolfenden pointed out, is a different kind of “race to the start line”: one where the finish line is measured in lives saved and futures extended. As the first episode in the series, the dialogue with Caris Life Sciences set a high standard for Race to the Start Line. It showcased how innovation, when combined with purpose, can shape industries—and in this case, save lives. 

Welcome to Episode 126 of The Perfectionist's Guide to Mothering! In this episode, I'm sharing another replay episode. This one is with Caris Snider all about how to help tweens with anxiety. She is the best-selling author of ⁠Anxiety Elephants: A 31 Day Devotional and Anxiety Elephants for Tween Girls⁠ ⁠and Boys⁠*.Some of the resources in this episode include: ⁠⁠Get a Mom's Guide for Back to School here⁠⁠⁠⁠Pre-order my book, Two-Minute Timeouts for New Moms: 100 Devotions for Weary and Wonderful Days.*⁠⁠⁠⁠⁠Join my book launch team.⁠⁠Psalm 94:191 Peter 5:7Philippians 4:8Psalm 91:11Philippians 4:4-6Matthew 6:25-34⁠Follow Me by David Platt*⁠⁠Rewire Your Anxious Brain by Catherine Pittman*⁠⁠The Tattooist of Auschwitz⁠ and ⁠Cilka's Journey by Heather Morris*⁠⁠Batiste Dry Shampoo*⁠GroupMe AppYou can connect with Caris via:⁠Her website: carissnider.com⁠⁠Instagram @carissnider⁠Her books: ⁠Anxiety Elephants: A 30 Day Devotional to Help Stomp Out Your Anxiety⁠*, ⁠Anxiety Elephants for Tween Girls⁠* and ⁠Anxiety Elephants for Tween Boys*⁠*Affiliate Link

Guests: Caris Snider & Del DuduitBook: Fierce: Female Athletes Fueled by FaithTheir websites: carissnider.com, delduduit.com

Guests: Caris Snider & Del DuduitBook: Fierce: Female Athletes Fueled by FaithTheir websites: carissnider.com, delduduit.com

Dr. George Sledge, Executive VP and Chief Medical Officer of Caris Life Sciences, is using advanced molecular testing, including DNA, RNA, and protein analysis, to identify specific mutations and characteristics of a patient's tumor, allowing for more personalized and targeted treatment. The company is developing liquid biopsies to detect cancer early, identify minimal residual disease, and assess the potential for future cancer development. Caris has a database of over half a million patients whose tumors have undergone next-generation sequencing, allowing them to draw increasingly accurate conclusions. The future of precision oncology is expected to involve broader and earlier use of next-generation sequencing as the cost of the test continues to decrease significantly. George explains, "Caris Life Sciences is a molecular diagnostics company. Patients and their physicians send us tumor samples that can be obtained either from the primary tissue or from a distant recurrent site. When they come to us, we do several things. We look at DNA, what's called whole exome. We look at RNA, what's called whole transcriptome. We also frequently look at the protein level at immunohistochemistry, looking at slides that have been stained to look for particular molecular lesions that may be important from a treatment standpoint. Based on all of these, we're able to provide patients with information about which drugs represent the most appropriate treatment for their disease. This, of course, allows you to go to a drug that hopefully will be less toxic and more effective for your particular disease."  "When we look at the very specific mutations that manifest themselves at the level of either DNA or RNA, this requires fairly high technology, what's called next-generation sequencing, which allows us to pick up all these individual mutations that make up a particular patient's cancer. And every patient's cancer is different. Every patient's cancer involves different combinations of mutations that result in different responses to different treatments." #CarisLifeSciences #CancerResearch #PrecisionMedicine #RealWorldData #AccestoCare #HealthEquity #NextGenerationSequencing #NGS #LiquidBiopsy #ClinicoGenomic #Biomarkers #PanCancer carislifesciences.com Download the transcript here

Dr. George Sledge, Executive VP and Chief Medical Officer of Caris Life Sciences, is using advanced molecular testing, including DNA, RNA, and protein analysis, to identify specific mutations and characteristics of a patient's tumor, allowing for more personalized and targeted treatment. The company is developing liquid biopsies to detect cancer early, identify minimal residual disease, and assess the potential for future cancer development. Caris has a database of over half a million patients whose tumors have undergone next-generation sequencing, allowing them to draw increasingly accurate conclusions. The future of precision oncology is expected to involve broader and earlier use of next-generation sequencing as the cost of the test continues to decrease significantly. George explains, "Caris Life Sciences is a molecular diagnostics company. Patients and their physicians send us tumor samples that can be obtained either from the primary tissue or from a distant recurrent site. When they come to us, we do several things. We look at DNA, what's called whole exome. We look at RNA, what's called whole transcriptome. We also frequently look at the protein level at immunohistochemistry, looking at slides that have been stained to look for particular molecular lesions that may be important from a treatment standpoint. Based on all of these, we're able to provide patients with information about which drugs represent the most appropriate treatment for their disease. This, of course, allows you to go to a drug that hopefully will be less toxic and more effective for your particular disease."  "When we look at the very specific mutations that manifest themselves at the level of either DNA or RNA, this requires fairly high technology, what's called next-generation sequencing, which allows us to pick up all these individual mutations that make up a particular patient's cancer. And every patient's cancer is different. Every patient's cancer involves different combinations of mutations that result in different responses to different treatments." #CarisLifeSciences #CancerResearch #PrecisionMedicine #RealWorldData #AccestoCare #HealthEquity #NextGenerationSequencing #NGS #LiquidBiopsy #ClinicoGenomic #Biomarkers #PanCancer carislifesciences.com Listen to the podcast here

Jacob Caris is an ex-corporate finance professional turned online entrepreneur who has generated over $7 million in sales through courses, coaching, consulting, and affiliate marketing—without relying on sales calls or big sales teams. After leaving Wall Street, Jacob built a business that prioritizes time freedom, lean operations, and high profit margins. As the founder of Caris Digital and Caris Investments, he's become a leading voice in helping coaches, consultants, and creators build lifestyle businesses that fund true freedom. On this episode we talk about: Jacob's journey from corporate finance and consulting to building a multi-seven-figure online business Making his first dollar online selling social signals and flipping websites before launching his personal brand The importance of proof-of-concept—how earning your first dollar online can be the catalyst for everything that follows Transitioning from affiliate marketing to launching high-ticket offers and group coaching programs The evolution from sales-driven to marketing-driven businesses, and why Jacob prefers content and trust over endless sales calls How to design a business around your ideal lifestyle and avoid the trap of chasing empty revenue milestones Jacob's “Five Page Google Doc System” for selling high-ticket offers without sales calls or sales reps Why qualitative factors—like peace of mind and time with family—matter as much as profit in business design The importance of interrogating your “why” and building a business that supports your real goals, not just what the internet says you should want Top 3 Takeaways Proof of Concept is Everything: Making your first dollar online—no matter how small—proves what's possible and gives you the confidence to keep building. Marketing-Driven > Sales-Driven: With the right content, audience, and offer, you can sell high-ticket products without endless sales calls or big teams—freeing up your time and boosting margins. Design Your Business for Your Life: Don't blindly chase revenue milestones. Get clear on your ideal day, week, and lifestyle, then build a business that supports those goals. Notable Quotes “If you can solve one very clear and real pain point people are sitting with right now, and give them a sexy, slightly different approach, you only need one offer to change your life forever.” “You run a marketing-driven business or a sales-driven business. Neither is wrong, but I prefer to build a business where content and trust do the heavy lifting.” “Don't let sunk cost fallacy keep you climbing the wrong mountain. Interrogate your ‘why' and make sure you're building the life and business you actually want.” Connect with Jacob Caris: Website: jacobcaris.com

Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the firm will steer its portfolio toward returns for shareholders, while aiming to build a new fund away from public markets. The analysts then assess Eli Lilly's takeout of cardiovascular base editing company Verve, and what Washington Editor Steve Usdin calls FDA's new “two-track” future for evaluating new therapies for approval — those with clear-cut benefits and those with ambiguous efficacy safety and efficacy profiles — in light of the many departures of senior FDA staff. They also discuss NASDAQ's largest biopharma IPO — by Caris —  in two years, the latest obesity readouts, FDA Commissioner Marty Makary's priority pathway and Usdin's Q&A with new BIO Chair Fritz Bittenbender. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656266#biotech #biopharma #pharma #lifescience #finance #CV #FDA00:01 - Sponsor Message: ICON Biotech02:14 - Syncona Restructures Fund10:08 - Lilly's $1B Verve Takeout21:45 - FDA's 2-Track FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Caris Life Sciences (CAI) CEO Brian Brille discusses their IPO and using AI in medical care. Caris is a precision oncology company that offers personalized treatment using genomic sequencing and data. “We're a pioneer in genomics…more information equals more power.” He explains the company's process and why AI is a useful tool in the field. He also talks about their unusual partnership structures with other companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Join co-host Jo Weston and Emily Mannix each week for BackStoppers: The Podcast presented by Deakin University. Get a sneak peek into their lives as they talk about everything from netball to their dogs. This week Maggie Caris joins Jo!

လူသားများသည် အပြစ်သားဖြစ်သောကြောင့်၊ ထာဝရအပြစ်၏တန်ဖိုးကို ပေးဆပ်ရသော်လည်း ခရစ်တော်သည် လူသားတို့အတွက် အပြစ်၏စျေးနှုန်းကိုယူကာ လူသားတို့ကို အပြစ်မှကယ်တင်ခဲ့သည်။ သဘာဝအကြောင်းအရာ။ ဓမ္မသီချင်း။ တရားဒေသနာ။

သခင်ခရစ်တော်သည် ဤလောကသို့ ပထမဆုံးအကြိမ်ကြွလာခြင်းသည် သူ၏ဒုတိယအကြိမ်ကြွလာခြင်းကို အရိပ်အယောင်ပြနေသည်။ ခရစ်တော်သည် ကယ်တင်ခြင်းအစီအစဉ်ကို တိကျစွာဆောင်ရွက်ခဲ့သည်။ သဘာဝအကြောင်းအရာ။ ဓမ္မသီချင်း။ တရားဒေသနာ။

In this episode, we're thrilled to have our guest Caris join us! Get ready for a lively discussion as we explore the hilarious idea of a nightmare blunt rotation, share which body part we'd choose to apologize to, and reminisce about our unforgettable 21st birthday celebrations.Sponsor:https://www.instagram.com/attorneydallas/Socials:https://www.instagram.com/brewsandbanter_pod/

Hi, I'm Caris, and welcome back to my channel—your go-to resource for navigating life with tinnitus! Whether you're here for practical advice, personal stories, or just a bit of encouragement, you're in the right place

Kühlschrank, Toaster, Staubsauger, Wecker, Klobürste - es gibt viele Gegenstände, die man im Haushalt tagtäglich benutzt. Wir bewerten heute typische Haushaltsgegenstände und -geräte. Am Ende haben wir eine besondere Challenge für euch!   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsor Lingoda: Commit to your New Year's resolution with the Lingoda Flex. Get a 10% discount and up to 45 free private classes when you sign up today with our code EASYPOD2025: try.lingoda.com/EasyPod2025 Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Top oder Flop: Haushaltsgegenstände Caris neuer Staubsauger: Dyson V12 Detect Slim Absolute Manuels Lichtwecker: PHILIPS SmartSleep Wake-up Light   Wichtige Vokabeln in dieser Episode das Haushaltsgerät: Gerät oder Maschine, die in der Wohnung oder im Haus verwendet wird, um alltägliche Aufgaben zu erleichtern, wie z.B. Kochen, Putzen oder Wäschewaschen der Gegenstand: Ding oder Objekt, das man berühren kann und das einen bestimmten Zweck oder Nutzen hat die Truhe: großer, oft rechteckiger Behälter mit Deckel auswringen: Flüssigkeit aus einem feuchten oder nassen Objekt entfernen, indem man es fest zusammendrückt und verdreht das Luxusgut: Gegenstand von hoher Qualität und oft hohem Preis, den man nicht zwingend braucht der Zungenbrecher: Satz oder Phrase, die schwer auszusprechen ist   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership

The boys discuss nerdy news on todyay's Nerd Report like David Lynch's passing, Elon Musk's lying about his gaming skills, and the announcement of the Nintendo Switch 2. Also, what is the origin of the practice of knocking on wood? CJ and Spenny discover on today's Did You Know!? And Austin Chronicle editor Caris stops by to highlight this year's Music Awards poll. Support the show: https://www.101x.com/cjSee omnystudio.com/listener for privacy information.

Caris, Kenny, and the Cavs destroyed the Nets in Brooklyn, behind a tremendous bench showing and super efficient frontcourt play.  Caris exploded for 19 in the first half, Georges cut up the Nets on the interior, and Kenny got a win against his former team as the Cavs set the stage for a matchup with the Bucks on Friday. Bob Schmidt, of Fox Sports Radio, breaks it all down.

Lauren Caris Cohan is a filmmaker and the chief creative officer of the chic and sustainable womenswear brand Reformation. Lauren got her start as a styling assistant at Free People in Philadelphia in the late 2000s, eventually working her way up to the title of artistic director. While looking to pursue a newfound interest in screenwriting, she was given carte blanche to create a series of narrative short films for the brand. In 2017, she left the company to look for new opportunities to explore filmmaking. She consistently worked on her projects, creating short films, writing scripts, and co-founding a creative services agency called Lolly Would. In 2017, she co-founded the industry-disrupting lingerie brand Cuup, again bringing her distinctive creative flair to craft the storytelling around the start-up. In 2020, she was brought in by Reformation to consult on projects, and in 2022, she was appointed the role of chief creative officer. In her time as CCO, she's guided Reformation through some truly amazing collaborations—from the New York City Ballet to Monica Lewinsky.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For another take on Catholic parts work look like in action, join Marion Moreland as she accompanies Caris in connecting, understanding, and loving Caris' parts – not just the manager parts who are usually in front, but also some of Caris' hidden exiled parts in this demonstration. Sarah is present in an observing role. This demonstration illustrates very typical ways of accompanying parts in inner work. Marion and Caris address themes of striving for productivity and perfection, control and rebellion, the pain of love rejected, among others and escape, and self-soothing. You are invited into the “observer role” with Sarah to connect with your own parts in your human formation as you experience the demo and your parts resonate with parts coming up in Caris' work. 

JCO PO author Dr. Alok A. Khorana, MD, FASCO, Professor of Medicine, Cleveland Clinic and Case Comprehensive Cancer Center, shares insights into the JCO PO article, “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.” Host Dr. Rafeh Naqash and Dr. Khorana discuss how multiomic analysis shows higher FGFR2 fusions and immunotherapy marker variations in early-onset biliary cancer. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO POarticles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today, we are joined by Dr. Alok A. Khorana, Professor of Medicine at the Cleveland Clinic and Case Comprehensive Cancer Center, and also the Senior Author of the JCO Precision Oncology article titled, “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.”  At the time of this recording, our guest disclosures will be linked in the transcript.  Dr. Khorana, it's an absolute pleasure to have you here today, and welcome to the podcast. Dr. Alok A. Khorana: Thank you. It's an absolute pleasure to be here and thank you for highlighting this article. Dr. Rafeh Naqash: Absolutely. We're going to talk about science, obviously, and a few other things. So to start off, for the sake of our audience, which comprises academicians and community oncologists as well as trainees, can you tell us a little bit about biliary tract cancers, what we have learned over the last decade or so, where the standard of treatment currently lies. And then we can dive into the article that you published. Dr. Alok A. Khorana: As many of you who treat GI cancers know, biliary tract cancers for a long period of time were sort of the orphan cancer in the GI cancer world. They're not nearly as common as, say, pancreatic cancer, and certainly not as common as colorectal cancer. They're sort of also, in this weird ‘no man's land' between well known sort of adjuvant therapy trials in pancreatic cancer or colorectal cancer, but because they're not as high in volume, there weren't really large trials done in this population. What's really changed in the past decade, especially, has been the slow but sure realization that biliary tract cancers are in fact a target rich cancer, almost similar to what you would see with lung cancer, and that's only a slight exaggeration. And in some studies, as many as up to 40% of patients with biliary tract cancers can have something that's targetable. And that's really revolutionized the way we think of biliary tract cancers. It also separated this field from pancreatic cancer where formerly the two used to be lumped together, and even within biliary tract cancers, we are now slowly realizing that there are differences between intrahepatic, extrahepatic and gallbladder cancers. Big change is really afoot in this field, particularly with the identification of mutation directed targets. Dr. Rafeh Naqash: Thank you for that explanation.  Now, another question I have is, although I don't see any GI cancers, but I have good colleagues of mine at our cancer center who see a lot of GI pancreatic/biliary cancers, and one of the things that comes up in our molecular tumor board often is how certain cancers of unknown primary end up being identified or categorized as biliary tract cancers based on NGS. And again, the uptake for these NGS is perhaps isn't optimal in the field yet, but in your practice, how do you approach situations like that? Do you use NGS in certain cases where the tissue of origin or the patterns of the mutations indicate that this might be biliary tract cancer and then treat the patient accordingly?  Dr. Alok A. Khorana: Yeah, that's true. And that's certainly how I approach things, and I would say even in my own personal practice, that has been a change. I was a little bit skeptical about the benefit of sort of tissue of origin type of testing in carcinoma of unknown, primarily, especially if you can sort of narrow it down to one or other area of the GI tract. But with the identification of sort of targeted subpopulations, especially of biliary tract cancer, I think it's become imperative. And I know we're going to get into the paper, but if you want to learn nothing else from this 20, 25 minute podcast, one lesson I just want to make sure everybody gets is that any patient with biliary tract cancer should have NGS done as soon as possible. Dr. Rafeh Naqash: Thank you for highlighting that important aspect.  Now, going to the topic at hand, what was the driving factor? I've heard a lot about colorectal cancers, early onset versus later onset. What was the reason that you looked at biliary tract cancers? Is that something that you've seen on a rise as far as early onset biliary tract cancers is concerned?  Dr. Alok A. Khorana: Yeah. So we got into this subject also from starting out at colorectal cancer. And as you know, and I'm sure most of your audience knows, there's been a lot of literature out there over the past five, six, seven years suggesting and then documenting and then sort of proving and reproving that colorectal cancer is on the rise, and especially in people younger than age 50. And even in that population, it's on the rise in two different subpopulations, people in their 20s and 30s and then people in their 40s that are close to the screening colonoscopy rates. That's been investigated heavily. We still don't fully understand why that's happening, but it's not restricted to the United States. It's a worldwide phenomenon. You can see it in the United States, in North America. You can see it in western Europe, but you can also see it in many Asian countries with specific sort of subpopulations. For instance, in some countries, men are more likely to have early onset cancers.   And then a newer finding that sort of emerged over the past couple of years is that this early onset increase in cancers is not just restricted to colorectal cancer, although that's the one that sticks out the most, but in fact, is widespread across a bunch of different types of cancers. In my own research program, we had gotten into a sort of better understanding of early onset colorectal cancer a couple of years ago, driven primarily by the sort of patients that I saw in my practice. And it's just, as you know, when you have a couple of those heartbreaking cases and they're just impossible to forget, and it sort of just drives your attention, and then you want to do something to help them. And if you can't help them personally, then you want to do something that can change the field so that more of these patients are not coming in your clinic next year or the year after.  So a couple years ago, at the Cleveland Clinic where I practice, we created a center for young onset cancers, and at the time it was primarily focused on colorectal cancer. But as we are getting into colorectal cancer, we realize that beyond colorectal cancer, we are also starting to see more younger people with other cancers, including pancreas cancer, including gastric cancer, and including bile duct cancers. And we realized that because so much attention was being focused on colorectal, that maybe we should also be paying a little bit of attention to what was happening in this space. I want to, for your listeners, point out that the problem in bile duct cancers is not to the same degree as you see in colorectal cancer. Just a couple numbers to sort of, to set this in perspective: about 5%, 7% of bile duct cancers are young onset - it's not a huge proportion - 90%+ percent of patients are not young onset. But the impact on society, the impacts on those providing care, is obviously substantial for younger patients. And it is true that even though the proportion of patients is not that high, the incidence is rising.   And there's a very nice study done a couple of years ago and published that looked at what the cancers are that are rising at the highest rates. And bile duct cancer and gallbladder cancers were listed amongst the two with the highest rate, so about an 8% rate per year of increase. And so that's really what drove our interest was, as we're seeing early onset bile duct cancers, it's rising year by year, and what is this disease? Is it the same as you see in sort of the average patient with bile duct cancer? Is it different? How do we characterize it? How do we understand it? What are some of the causes precipitating it? And so that's what led us to sort of one of the investigations that we've documented in this paper.  Dr. Rafeh Naqash: Excellent.   So, talking about this paper, again, can you describe the kind of data that you use to understand the molecular differences and also look at potential immune signatures, etc., differences between the groups? Dr. Alok A. Khorana: Yeah. So the objective in this paper was to look at genomic differences between early onset and usual onset, or average onset biliary tract cancers. And this sort of followed the paradigm that's already been established for early onset colorectal cancer, where you take a bunch of people with early onset disease, a bunch of patients with average onset or usual onset disease, and then look at the profiling of the tumors. And we've done this for genomics, we've done this for microbiomics, we've done it for metabolomics. And the lessons we've learned in colorectal cancer is that, in many ways, the profiles are actually quite substantially different. And you can almost think of them as diseases of the same organ, but caused by different processes, and therefore leading to different genotypes and phenotypes and microbiomes. We had absorbed that lesson from colorectal cancer, and we wanted to replicate it in this type of cancer.  But as we discussed earlier, this is a relatively rare cancer, not that many cases per year. For colorectal, we could do a single institution or two institution studies. But for this, we realized we needed to reach out to a source of data that would have access to large national data sets. We were happy to collaborate with Caris Life Sciences. Caris, many of you might know, is a provider of genomics data, like many other companies, and they house this data, and they had the age categorization of patients less than 50, more than 50. And so we collaborated with investigators at Caris to look at all the specimens that had come in of bile duct cancers, identified some that were young onset and some that were older onset. It was roughly about 450 patients with the early onset or young onset, and about 5000 patients with usual onset cases. And then we looked at the genomics profiling of these patients. We looked at NGS, whole exome sequencing, whole transcriptome sequencing, and some immunohistochemistry for usual, like PDL-1 and MSI High and things like that. And the purpose was to say, are there differences in molecular profiling of the younger patient versus the older patient? And the short answer is yes, we did find substantial differences, and very crucial for providers treating these patients is that we found a much higher prevalence of FGFR2 fusion. And that's important because, as I'm sure you've heard, there's a ton of new drugs coming out that are targeting specifically FGFR fusion in this and other populations. And hence my statement at the outset saying you've got to get NGS on everybody, because especially younger patients seem to have higher rates of some of these mutations.  Dr. Rafeh Naqash: Excellent. You also looked at the transcriptome, and from what I recollect, you identified that later onset tumors had perhaps more immune favorable tumor microenvironment than the early onset. But on the contrary, you did find that FGFR2 early onset had better survival. So how do you connect the two? Is there an FGFR link, or is there an immune signature link within the FGFR cohort for early onset that could explain the differences? Dr. Alok A. Khorana: Yeah, that's a great question. So, to kind of summarize a couple of these things you talked about. So, one is we looked at these genomic alterations, and, yes, FGFR2 fusion was much more prevalent. It's close to 16% of young onset patients, as opposed to roughly 6% of average onset patients. So almost a threefold increase in FGFR fusion. And because there's so many drugs that are targeting FGFR fusion, and because the population included a period of time when these drugs had already been approved, we think some of the benefit or the improvement in median survival associated with being younger is likely driven by having more FGFR fusion and therefore having more drugs available to treat FGFR fusion related tract cancer with corresponding increase and increase in survival. And that was part of it. There was one other alteration, NIPBL fusion, that's been sort of known to be associated with a certain subtype of cholangiocarcinoma, but it doesn't really have a drug that targets it, so it's not sort of very useful from a clinical perspective.   The other two things you talked about, so transcriptome and immuno oncology markers, we found a couple different results on this. So one is that we found in younger people, angiogenesis was enriched, and why this is so we don't quite have a good answer for that. The other was inflammatory responses. So there's a couple of gamma interferon pathways and a couple other types of pathways that you can sort of do pathway analysis, and we found that those were enriched in the older patients or the average onset patients. But the benefit for immunotherapy was similar across the two groups. So even though we saw these differences in signaling in terms of which pathways are upregulated or downregulated, it didn't seem to translate into the current generation of immune checkpoint inhibitors that we're using in terms of benefit for patients. But we did see those differences.  Dr. Rafeh Naqash: I completely agree, Doctor Khorana. As you mentioned, that one size fits all approach does not necessarily work towards a better, optimal, personalized treatment stratification. So, as we do more and more sequencing and testing for individuals, whether it's early onset cancers or later onset cancers, figuring out what is enriched and which subtype, I think, makes the most sense.   Now, going to the FGFR2 story, as you and most listeners probably already know, FGFR is an approved target, and there are a band of FGFR inhibitors, and there's some interest towards developing specific FGFR2, 3 fusion inhibitors. What has your experience with FGFR inhibitors in the clinic been so far? And what are you personally excited about from an FGFR standpoint, in the drug development space for GI cancers?  Dr. Alok A. Khorana: Yeah, I think the whole FGFR fusion story sort of actually deserves more excitement than it's gotten, and it may be because, as I mentioned earlier, biliary tract cancers are a relatively low volume type of cancer. But the results that we are seeing in the clinic are very impressive. And the results that we are anticipating, based on some ongoing phase two and phase three trials, appear to be even more impressive for the very specific inhibitors that are about to hopefully come out soon.   Also, the possibility of using successive lines of FGFR inhibitors - if one fails, you try a second one; if the second one fails, you try a third one because the mechanisms are subtly different - I think it will take a little while to figure out the exact sequencing and also the sort of the rates of response in people who might previously have been exposed to an FGFR inhibitor. So that data may not be readily available, because right now most patients are going in for longer trials. But having that type of possibility, I think, kind of reminds me of the excitement around CML back when imatinib suddenly became not the only drug and a bunch of other drugs came out, and it's kind of like that. I think again, it's not a very common cancer, but it's really wonderful to see so many options and more options along the way for our patients. Dr. Rafeh Naqash: Thank you. Now, going to your personal story, which is the second part of this conversation, which I think personally, for me, is always very exciting when I try to ask people about their personal journeys. For the sake of the listeners, I can say that when I was a trainee, I used to hear about Dr. Khorana's course, I always thought that Dr. Alok Khorana was a hematologist. My friends corrected me a few years back and said that you're a GI oncologist. Can you tell us about your love for GI oncology and the intersection with hematology thrombosis, which you have had a successful career in also? Can you explain how that came about a little bit? Dr. Alok A. Khorana: Yeah, sure. So it is a common, I guess I shouldn't say misperception, but it's certainly a common perception that I'm a hematologist. But I'll sort of state for the record that I never boarded in hematology. I did do a combined hem-onc fellowship, but only boarded in oncology. So I'm actually not even boarded in hematology. My interest in thrombosis came about- it's one of those things that sort of happen when you're starting out in your career, and things align together in ways that you don't sort of fully understand at the time. And then suddenly, 10 years later, you have sort of a career in this.   But it actually came about because of the intersection of, at the time, angiogenesis and coagulation. And this is the late ‘90s, early two ‘00s, there was a lot of buzz around the fact that many of the factors that are important for coagulation are also pro angiogenic and many factors that are coagulation inhibitors. These are naturally occurring molecules in your body, and can be anticoagulant and anti angiogenic. A great example of this is tissue factor, which is, as you'll remember from the coagulation pathways, the number one molecule that starts off the whole process. But less widely appreciated is the fact that nearly every malignancy expresses tissue factor on its cell surface. This includes breast cancer, it includes leukemia cells, it includes pancreatic cancer. In some cancers, like pancreatic cancer, we've even shown that you can detect it in the blood circulation. And so for me, as a GI oncologist who was seeing a lot of patients get blood clots, it was particularly fascinating to sort of see this intersection and try and understand what is this interaction between the coagulation and angiogenic cascades that's so vital for cancers. Why is coagulation always upregulated in cancer patients? Not all of them get blood clots, but subclinical activation of coagulation always exists. So I would say I was fascinated by it as an intellectual question and really approached it from an oncology perspective and not a hematology perspective.   But then as I got deeper into it, I realized not everybody's getting blood clots, and how can I better predict which patients will get blood clots. And so I had both a hematology mentor, Charlie Francis, and an oncology mentor, Gary Lyman. And using sort of both their expertise, I drafted a K23 career development award specifically to identify predictors of blood clots in cancer patients. And that's the multivariate model that later became known as the Khorana Score. So again, I approach it from an oncology perspective, not a hematology perspective, but really a fascinating and still, I would say an understudied subject is why are cancer patients having so many clotting problems? And what does it say about the way cancer develops biologically that requires activation of the coagulation system across all of these different cancers? And I think we still don't fully understand the breadth of that. Dr. Rafeh Naqash: Very intriguing how you connected two and two and made it a unique success story. And I completely agree with you on the tissue factor. Now there's ADCs antibody drug conjugates that target tissue factor, both a prude as well as upcoming.   Now, the second part of my question is on your personal journey, and I know you've talked about it on social media previously, at least I've seen it on social media, about your interactions with your uncle, Dr. Har Gobind Khorana, who was a Nobel Prize winner in medicine and physiology for his work on DNA. Could you tell us about how that perhaps shaped some of your personal journey and then how you continued, and then also some personal advice for junior faculty trainees as they proceed towards a successful career of their own? Dr. Alok A. Khorana: Yeah, thank you for bringing that up. So very briefly, this is about my uncle. He's actually my great uncle. So he's my grandfather's youngest brother. And I grew up in India in the ‘70s and ‘80s, and at the time, I ran away from this association as fast as I could, because growing up in India in the 70s and ‘80s, it was a socialist economy. There wasn't a lot going on. There was certainly none of the IT industry and all of everything that you see right now. And so there were very few icons, and my great uncle was definitely one of those few icons. As soon as you mentioned your last name, that would sort of be the first question people would ask. But he did serve as a role model, I think, both to my father, who was also a physician scientist and a professor of medicine, and then to myself in sort of making me realize, one, that you can't really separate medicine from science. I think those are really integrated, and we want to ask questions and answer questions in a scientific manner. He chose to do it in a basic science world. My father did it in a clinical science world, and I have done it in a clinical and a translational science world. Again, sort of using science as the underpinning for sort of understanding diseases, I think, is key. And so that was certainly a massive inspiration to me.  And then after I immigrated to the US in the late ‘90s, I met him on a regular basis. He was certainly very inspirational in his successes, and I realized the breadth of what he had done, which I did not realize in my youth growing up. But this is a person who came to the US. This was before Asian immigration was even legal. So he got here and they had to pass a special bill in Congress to let him be a citizen that was based on the sort of work that he had done in Canada and in the UK before he came here. And then he sets up shop in the University of Wisconsin in Madison and hires tons of these postdocs and essentially converted his lab into this massive factory, trying to figure out the genetic code. Really just the type of dedication that that needs and the amount of work that that needs and the ability to do that in a setting far removed from where he grew up, I think it's just really quite mind boggling.  And then he didn't stop there. He got the Nobel for that, but I have these letters that he wrote after he got the Nobel Prize, and he was just completely obsessed with the possibility that getting the Nobel would make him sort of lose his mojo and he wouldn't be as focused on the next aspects of science. And he was just really dedicated to synthesizing DNA in the lab, so creating artificial DNA, which he ended up doing. And the offshoot of that work, so not just the genetic code, but PCR essentially was developed by his lab before it became sort of what we now know as PCR. And then ditches all of that in the ‘80s and ‘90s and moves to understanding the retina and just focuses on retinal disorders. And then signal transduction, essentially trying to figure out when a single photon of light hits your eye, what happens biologically. It's a completely different field. And just took that on and spent the next 20,30 years of his life doing that. So the ability to sort of change fields, I thought that was very inspirational as well, that you don't have to just stick to one question. You can get into one question, answer it as much as possible, and then find something else that's really interesting to you and that really grabs your attention, and then stick with that for the next couple of decades. So lots to learn there. Dr. Rafeh Naqash: Thank you. Thank you. And then, based on some of your personal lessons, what's your advice for junior faculty and trainees as you've progressed in your career?  Dr. Alok A. Khorana: I think, number one, and I can't emphasize this enough, and sometimes it actually causes a little bit of anxiety, but it is finding the right mentor. And for me, certainly that was key, because my mentor, who was Charlie Francis, was not an oncologist who was a hematologist, but was like me, sort of supported this idea of trying to understand, hey, why does coagulation interact with cancer? And so he approached it from a hematology perspective, I approached it from a cancer perspective, but he sort of gave me the freedom to ask those questions in his lab and then later on in the clinical setting and clinical translational setting, and then got me access to other people who are experts in the field and introducing you and then getting you on committees and making sure you sort of get into clinical trials and so on. And so having a mentor who sort of supports you but doesn't stifle you, and that's really key because you don't want to just ask the question that the mentor is interested in. And as a mentor now, I don't want to have my mentee ask the question that I'm interested in, but also a question that the mentee is interested in. And so there's a little bit of a chemistry there that's not always replicable, and it can go wrong in sort of five different ways, but when it goes right, it's really vital. And I mentioned it causes anxiety because, of course, not every day is great with your mentor or with your mentee, but over a period of time, has this person done sort of their best to get your career off to a start? And have you served that mentor well by doing the things that are– there's responsibilities on both sides, on both on the mentor and on the mentee. And if you can find that relationship where there's a little bit of chemistry there and both of you are effectively discharging both your responsibilities and satisfying your intellectual curiosity, I think that can't be beat, honestly. To me, sort of number one is that and everything else follows from that. So, the networking, making sure your time is sort of allocated appropriately, fighting with sort of the higher ups to make sure that you're not having to do too much, things that are sort of away from your research interests, all of that sort of flows from having the right person. Dr. Rafeh Naqash: Couldn't agree with you more, Dr. Khorana, thank you so much. It was an absolute pleasure. Thank you for sharing with us the science, the personal as well as the professional journey that you had. And hopefully, when you have the next Khorana Score, Khorana score 2.0, JCO Precision Oncology will become the home for that paper and we'll try to have you again maybe in the near future.  Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you so much.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Disclosures: Dr. Khorana  - Honoraria Company: Pfizer, Bayer,  Anthos, Sanofi, BMS, WebMD/MedscapeConsulting or Advisory Role Company: Janssen, Bayer, Anthos, Pfizer, Sanofi, BMS Research Funding Company: Anthos, Bristol-Myers,  Squibb Travel, Accommodations, Expenses Company: Janssen, Bayer, Bristol-Myers Squibb 

On todays show we welcome back guest Caris Snider, an author and speaker, to discuss the prevalent issue of anxiety among teenagers. Caris, who has written extensively on the subject, shares her insights, experiences, and results from a survey conducted with teens to uncover the symptoms and coping mechanisms associated with anxiety. The discussion covers the pressures teens face from academic expectations, social media, and societal norms, and emphasizes the importance of awareness, healthy coping strategies, and the role of faith.  The episode aims to empower moms with tools and knowledge to support their children through anxious seasons, highlighting that seeking professional help is a sign of strength, not failure. To connect with Caris:  Website~Anxiety Elephants for Teens~Instagram Connect with Courtney: Website~Instagram~Facebook

After another magnificent summer league outing, Jaylon Tyson demands coverage.  Today, Bob Schmidt is joined by the radio voice of the Cal Golden Bears, Justin Allegri, who shares stories of his experiences with Jaylon during his time at Cal.  Then we go to the audio mailbag, where Brett has thoughts about the future of Isaac and Mikal Bridges.  (0:00) Justin Allegri, the voice of the Bears talks Jaylon Tyson(21:25) Audio Mailbag: Brett Clapper on the future of Isaac and Caris

On this episode, Justin sits down with Doug Caris and Eric Rector of Arizona Painting Company. The discussion covers company growth, branding, state expansion, and commercial painting challenges. The conversation delves into their acquisition strategy, EOS implementation, client experience, training processes, and advice for those looking to one-up their sales and entrepreneurial game.

Earth's common earthworms live deep under soil while red wiggler worms prosper just under topsoil beneath decomposing organic matter. Robert, Olivia, Elliott, and Caris share what life is like in the 4th grade caring for worm buckets and how they use nutrients made from compost tea or castings.

One thing I love about author, speaker and life coach Caris Snider is her heart for God and her message on how to overcome anxiety with the Word of God! I guess that's really two things! This week, Caris gives us practical steps that we can take in order to not just deal with anxiety and depression, but overcome them once and for all! Ladies, there is hope! There is freedom!!Be sure to check out Caris Snider's new Devotional for Teens! This is a must-have book for everyone ages 13 through 18!Here's a little sneak peek below:From "Anxiety Elephants for Teens: a 90-Day Devotional:"Anxiety is more prevalent now in the lives of teens than ever before.As the world has become more confusing, and the pressures are on the next generation for a host of anxiety-inducing issues, teenagers may find themselves crippled under the weight of their fears. Nevertheless, Scripture has something to say about the mental health issues our teens face. Anxiety expert Caris Snider will walk readers through how to manage their symptoms and trust in God through this ninety-day devotional.Caris's relatable prose and kind voice will ease readers through their daily struggles as they see God's providential hand in their lives.As teens face an unprecedented world, ensure they are equipped with this guide on tackling their fears…and embracing the future God has paved for them.Anxiety Elephants for Teens: A 90-Day DevotionalAvailable March 5, 2024!  Pre-Order Your Copy Now:Amazon     Barnes & Noble     Christianbook   End Game PressThe Beautiful Movement now has the March box available for pre-sale! Grab your box before they sell out! The theme is “He is Risen,” a box to prepare your hearts for Easter! You don't want to miss this one! Go to www.jointhebeautifulmovement.com to sign up! Use discount code: uncommonteen for 15% OFF your 1st box! Ladies, we have had challenges recently with the UncommonTEEN App and you all haven't been able to ask your questions for our Ask Me Anything podcast episodes...so to make that easier for you, we added a brand new RED button at the top of the UncommonTEEN website that says, "Ask Me Anything!" If you want to submit your questions for upcoming Ask Me Anything episodes, be sure to head on over to UncommonTEEN.com and ask your questions there! Connect with Us!Website: UncommonTEEN.comInstagram: @uncommon.teenUncommonTEEN Live Conference: UncommonTEENlive.com

Caris Snider is a speaker, author, coach, and podcaster. Her latest book is There's an Elephant on My Chest, a picture book for children she wrote to help kids understand what anxiety feels like. Today, Caris shares her story of growing up in a Christian home in the Bible belt feeling like she had to be perfect. Trying to live up to her beliefs led to anxiety and depression until she was willing to accept help. Caris shares with us how she found hope over anxiety and the Lord's closeness during the process. Caris' story reminds us that we need community and don't have to be perfect to be loved. Listen to Caris' story in your favorite podcast player today! Children's Picture Book- There's an Elephant on My Chest Stories Caris shared: Overcoming anxiety and helping others Growing up in Alabama in a Christian family as a twin Her mom's example as a prayer warrior Having to overcome cerebral palsy on the left side of her body Trying out for cheerleader and not making it Studying early childhood development Meeting her husband who was in a Christian boy band Buying her own childcare center and realizing that it wasn't for her The season of uncertainty after giving up the childcare center Trying to pull herself up by her bootstraps and finding it impossible Having anxiety attacks with increasing frequency Trying to numb her pain by not eating Having a miscarriage and how that affected her Realizing she had to accept help to get out of her depression Giving up the idea of perfection for herself Learning the identities that the Lord has for her Writing books about anxiety and helping others Great quotes from Caris: When I looked up the things I was believing were proven to be lies. I had to recognize that help was not bad. I had to stop believing that I had to be perfect to be loved by Him. Those struggles are real but there is real hope. Resources we mentioned: Caris' website There's An Elephant On My Chest by Caris Snider Car Line Mom Devotional: 100 Days of Encouragement for the Mama Who Gets Everybody Everywhere by Caris Snider Related episodes: Edith Leland and Intimate Friendship with God Jon Fugler and Ditching Performance Christianity Christy Boulware and Love That Casts Out Fear The post Caris Snider and Hope Over Anxiety appeared first on Eric Nevins.

Caris Snider is a speaker, author, coach, and podcaster. Her latest book is There’s an Elephant on My Chest, a picture book for children she wrote to help kids understand what anxiety feels like. Today, Caris shares her story of growing up in a Christian home in the Bible belt feeling like she had to be […] The post Caris Snider and Hope Over Anxiety appeared first on Eric Nevins.

Manuel ist im Urlaub und Caris Freund Klaus ist zu Gast im Podcast. Klaus berichtet von seinen Erfahrungen im Zeltlager am vergangenen Pfingstwochenende und vom Verkehrslärm, der ihn in letzter Zeit genervt hat. Im Anschluss sprechen Cari und Klaus über seinen Alltag als Lehrer in Deutschland und vergleichen, inwiefern sich sein Tagesablauf von Caris unterscheidet.   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsoren Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Zu Gast: Klaus Spargel-Wahnsinn: Wir kochen das Lieblingsgemüse der Deutschen (Easy German 504) At the Emsland (Easy German 53) German Traditions: Boßeln (Easy German 189) Fußball in Deutschland (Easy German Podcast 124)   Wichtige Vokabeln in dieser Episode das Zeltlager: Ort, an dem Menschen in Zelten übernachten, oft im Freien und für eine begrenzte Zeit der Pfadfinder: Mitglied einer Jugendorganisation, die Outdoor-Aktivitäten, Gemeinschaft und persönliche Entwicklung fördert frösteln: leicht zittern oder sich kalt fühlen, oft aufgrund von Kälte oder Unbehagen die Einfachverglasung: Fenster mit nur einer Glasschicht, das sehr dünn ist und deshalb u. a. viele Geräusche und Lärm durchlässt der Ganztagsunterricht:Schulform, bei der Schüler den ganzen Tag in der Schule verbringen, einschließlich Mittagessen und zusätzlicher Aktivitäten die Mensa: Speisesaal oder Cafeteria in einer Schule, Universität oder anderen Bildungseinrichtung, in dem Mahlzeiten angeboten werden   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership